HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Unilever Looks To Personal-Care Innovation, Improved “Agility” In FY 2014

This article was originally published in The Rose Sheet

Executive Summary

Unilever reports a 3% decline in FY 2013 turnover, but underlying sales growth was ahead of market, the firm says, crediting strong innovation in personal care and successes in emerging markets, among other factors. Going forward the firm aims to create efficiencies via SKU reductions and other streamlining efforts.

You may also be interested in...



Unilever China Reports 20% Drop In Underlying Sales Growth In Q3

Unilever’s China business recorded a 20% decline in underlying sales growth and major product destocking in the third quarter, the Anglo-Dutch firm announces Oct. 23, stunning some analysts. The company’s European business struggled with difficult weather conditions and price deflation, while in North America the firm is seeing modest signs of improvement.

Hair Care Success In 2013 Reflects Innovation, Uptake In Emerging Markets

Shampoo sales propelled hair-care growth around the world in 2013, and 90% of global shampoo growth came from emerging markets, according to Euromonitor’s Oru Mohuiddin. Meanwhile, innovations in conditioners and colorants drove gains in developed markets and helped offset headwinds that created greater drag for skin care and color cosmetics last year, she says.

In Brief: IND Applications For Cosmetic Trials? Lauder Appointment; P&G At Olympics

Comments may be submitted through April 7 regarding cosmetics-related sections in an FDA guidance that could impose the costs and burden of Investigational New Drug application on beauty companies conducting clinical trials. More news in brief.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS019327

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel